Macromolecular chemotherapeutics

US11116844B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11116844-B2
Application numberUS-201916577142-A
CountryUS
Kind codeB2
Filing dateSep 20, 2019
Priority dateNov 9, 2017
Publication dateSep 14, 2021
Grant dateSep 14, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Embodiments of the invention are directed to a macromolecular chemotherapeutic. A non-limiting example of the macromolecular chemotherapeutic includes a block copolymer. The block copolymer can include a water-soluble block, a cationic block, and a linker, wherein the linker is connected to the water-soluble bock and the charged block.

First claim

Opening claim text (preview).

What is claimed is: 1. A macromolecular chemotherapeutic, comprising: a block copolymer comprising: a water-soluble block, a cationic block, the cationic block comprising a polymeric subunit comprising a polycarbonate backbone having from 4 to 8 atoms; a linker, wherein the linker is connected to the water-soluble bock and the charged block; and an endcap bound to the cationic block having the structure: wherein which R8 is a long chain alkyl group, a polylactide, or a cholesterol. 2. The macromolecular chemotherapeutic of claim 1 , wherein the water-soluble block comprises polyethylene oxide. 3. The macromolecular chemotherapeutic of claim 2 , wherein the polyethylene oxide has an average molecular weight of 2000 to 20,000 daltons. 4. The macromolecular chemotherapeutic of claim 1 , wherein the linker is a cleavable linker. 5. The macromolecular chemotherapeutic of claim 3 , wherein the cleavable linker comprises an acetal or a disulfide. 6. The macromolecular chemotherapeutic of claim 1 , wherein the cationic block includes polymeric subunit comprising a polycarbonate backbone having from 6 to 8 atoms. 7. A method of inhibiting cancer stem cell growth comprising: providing a culture of cancer cells, comprising a plurality of cancer stem cells; incubating the cancer stem cells with a solution comprising a plurality of micelles, wherein the micelles comprise the macromolecular chemotherapeutic of claim. 8. The method of claim 7 , wherein the cationic block includes a polymeric subunit comprising a polycarbonate backbone having from 6 to 8 atoms. 9. A method of treating cancer, comprising: administering to a mammal in need thereof an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the chemotherapeutic of claim 1 . 10. The method of claim 9 further comprising killing cancer cells of the mammal by necrosis. 11. The method of claim 9 , wherein the water-soluble block comprises polyethylene oxide. 12. The method of claim 11 , wherein the polyethylene oxide has an average molecular weight of 2000 to 20,000 daltons. 13. The method of claim 9 , wherein the cleavable linker comprises an acetal. 14. The method of claim 9 , wherein the cleavable linker comprises a disulfide. 15. A method of synthesizing the macromolecular chemotherapeutic of claim 1 , comprising: forming a mixture comprising a cyclic carbonyl monomer comprising a cyclic carbonyl group having a cationic sidechain with a macroinitiator selected from the group consisting of a polyethylene glycol comprising an acetal and a methoxypoly(ethylene glycol), and an organocatalyst, and agitating the mixture at a time sufficient to form a block copolymer. 16. The method of claim 15 , wherein the mixture comprises an accelerator. 17. The method of claim 15 further comprising combining the block copolymer with a tertiary amine. 18. The method of claim 17 , wherein the tertiary amine comprises cholesterol or a cholesterol derivative. 19. The method of claim 15 , wherein the block copolymer is self-immolative at a pH less than or equal to 6.5.

Assignees

Inventors

Classifications

  • A61K31/785Primary

    Polymers containing nitrogen · CPC title

  • Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule · CPC title

  • containing carboxyl groups, or halides, or esters thereof · CPC title

  • Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title

  • Polyalkylene oxides · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11116844B2 cover?
Embodiments of the invention are directed to a macromolecular chemotherapeutic. A non-limiting example of the macromolecular chemotherapeutic includes a block copolymer. The block copolymer can include a water-soluble block, a cationic block, and a linker, wherein the linker is connected to the water-soluble bock and the charged block.
Who is the assignee on this patent?
IBM, Agency Science Tech & Res, Agency For Science Tech
What technology area does this patent fall under?
Primary CPC classification A61K31/785. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).